No connection

Search Results

BMRA vs LUCY

BMRA
Biomerica, Inc.
BEARISH
Price
$2.57
Market Cap
$7.8M
Sector
Healthcare
AI Confidence
95%
LUCY
Lucyd, Inc
BEARISH
Price
$1.10
Market Cap
$6.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BMRA
--
LUCY
--
Forward P/E
BMRA
6.59
LUCY
-2.44
P/B Ratio
BMRA
1.71
LUCY
0.67
P/S Ratio
BMRA
1.74
LUCY
2.6
EV/EBITDA
BMRA
-1.06
LUCY
-0.05

Profitability

Gross Margin
BMRA
5.63%
LUCY
21.32%
Operating Margin
BMRA
-113.47%
LUCY
-260.39%
Profit Margin
BMRA
-90.31%
LUCY
-285.2%
ROE
BMRA
-84.3%
LUCY
-83.6%
ROA
BMRA
-49.44%
LUCY
-53.15%

Growth

Revenue Growth
BMRA
-26.0%
LUCY
39.0%
Earnings Growth
BMRA
--
LUCY
--

Financial Health

Debt/Equity
BMRA
0.06
LUCY
--
Current Ratio
BMRA
3.25
LUCY
9.03
Quick Ratio
BMRA
2.18
LUCY
6.68

Dividends

Dividend Yield
BMRA
--
LUCY
--
Payout Ratio
BMRA
0.0%
LUCY
0.0%

AI Verdict

BMRA BEARISH

The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating extremely weak fundamental health. Despite a seemingly healthy Current Ratio of 3.25 and low Debt/Equity of 0.06, the company is plagued by deep profitability issues, including a -90.31% profit margin and -84.30% ROE. Revenue has declined by 26% year-over-year, and the stock has lost 95.7% of its value over five years, reflecting persistent operational failures and lack of investor confidence. The absence of an Altman Z-Score due to incomplete data further limits confidence in solvency assessments, but the overwhelming negative trends in earnings, margins, and price performance dominate the outlook.

Strengths
Low Debt/Equity ratio of 0.06 suggests minimal leverage risk
Current Ratio of 3.25 indicates strong short-term liquidity
Quick Ratio of 2.18 supports near-term financial flexibility
Risks
Piotroski F-Score of 1/9 signals critical weakness in earnings, leverage, and operating efficiency
Profit margin of -90.31% and operating margin of -113.47% reflect severe unprofitability
Revenue growth down 26% YoY, indicating shrinking top line and possible market rejection
LUCY BEARISH

LUCY exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows strong top-line revenue growth of 39% and a consistent track record of beating earnings estimates, these are overshadowed by a catastrophic profit margin of -285.20% and a 5-year price collapse of 99.1%. The high current ratio (9.03) suggests a temporary liquidity cushion, but the overall trajectory remains highly speculative and fundamentally unstable.

Strengths
Strong YoY revenue growth of 39.00%
Consistent earnings beats (4/4 in the last 4 quarters)
High liquidity with a current ratio of 9.03
Risks
Extreme operational inefficiency (Profit Margin: -285.20%)
Critical fundamental health (Piotroski F-Score: 1/9)
Severe long-term capital erosion (-99.1% 5-year change)

Compare Another Pair

BMRA vs LUCY: Head-to-Head Comparison

This page compares Biomerica, Inc. (BMRA) and Lucyd, Inc (LUCY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile